i never thought of it that way, but thats why you are the SK...I have been trying to figure it out but I certainly dont know. One thing I thought of is that this purchase size very similar in size that Perspective bought back on July 23rd...thought maybe it was a late settlement from that price...I like your theory better
i saw it to 835,000 shares at 12.36 pps is over 10 million dollar transaction...i checked sec dot gov and acrx investor section and i dont see any filings...i hardly think that size is a typo. there is a conference tomorrow morning at 11:30 est but who knows
stillondgo, history should have told us it would get smacked down after 52 wk high just like it did...I was poised to sell half and buy dips, but couldnt pull the trigger this time. It happens. Nevertheless, I think it bounces hard if it touches 11 area or just below. ALSO DONT FORGET ROTH CONFERENCE TOMORROW - I dont expect any huge news but it typically moves the stock up a little.
Not sure where the bottom is...long term chart looks really good. A week ago today it bounced hard from the 11 area...we shall see
Just a guess, but I think Annie is referenccing the official Phase 3 initiation announcement of ARX04. We have received guidance of their plan to start in the second half of 2014, but no official statment (or PR) that the p3 trial has has started. Also, will the DOD help fund the third trial? Someone posted that they got a reply from IR that the DOD funding is a challenge due to budget constraints with the govtt, but will not stop P3. So the ARX04 announcement is not imminent, imo, but not too far down the road.
"These additional analyses of data from our Phase 2 study demonstrate a rapid onset of action and a sustained strong analgesic effect for ARX-04 (30 mcg), a non-invasive, healthcare provider-administered analgesic product candidate for the short-term treatment of moderate-to-severe acute pain where intravenous access may not be desirable or readily available," stated Dr. Pamela Palmer, Chief Medical Officer, AcelRx Pharmaceuticals. "These data will be reviewed in our End-of-Phase 2 meeting with the FDA later this month in order to define the Phase 3 development program for ARX-04, which we hope to initiate in the second half of 2014."
From Life Science report, Chin Lenn
TSLR: How is the AcelRx stock performing?
CL: The stock has been very volatile—which is a good thing! As I tell my subscribers, my investment strategy is very simple. I buy when a stock is in the single digits; I sell when it reaches double digits. I originally bought AcelRx at a few dollars per share. I sold a portion of it when it reached $13/share. Then it dropped to $8/share, and I bought again. I sold it again when the price hit $11–12/share. Now, it is around $12/share. We shall see if it drops to a single digit again. Then I shall buy more! I hold a strong position in AcelRx and use it to trade in and out. It is still a very good buy, with lots of upside, because the FDA approval is probably worth $30–40/share. Buy low, sell high!
it would be naive of us to think that 5 million shorts would go away quietly...still holding - know what we have
just from yahoo as of 2/14...insiders 49%, Institutions 30%...5 million short...24% float short...we shouldn't be shocked of the volatility. combine that with IBB volatility acrx is moving violently in both directions
Profit taking, new retail owners, and the IBB index causing a perfect storm. Nothing has changed with the company since it touched the 52 wk high yesterday. I didn't sell any of my holdings to capitalize on this swing, but I did pick up some more at 12.20. GL
fwiw - I have been watching L2 closely. A big ask amt comes in and it is quickly snapped up at the ask price. The small lots are just going up and down by retail. Luckily, the big asks are being snapped up.